Coherus Presents Preliminary Results from Phase I Dose : vim

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective...

Related Keywords

Chicago , Illinois , United States , Mccormick Place , Rosh Dias , Jodi Sievers , Coherus Biosciences , Jami Taylor , Corporate Communications , Nasdaq , Abbvie Inc , Exchange Commission , Exchange Commission On , Amgen Inc , Coherus Biosciences Inc , Coheru Chief Medical , Preliminary Results , Dose Escalation Study , Advanced Solid , Developmental Therapeutics , Neck Squamous Cell Carcinoma , Private Securities Litigation Reform Act , Coheru Quarterly Report , Contact Information ,